Roniciclib BAY-1000394 is a promising drug compound that is currently being developed for the treatment of cancerous tumors. It is a potent inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), enzymes that are crucial for cancer cell proliferation. In preclinical studies, Roniciclib has exhibited strong anti-tumor activity in various forms of cancer such as breast, lung, and pancreatic cancer. In this article, we will provide a detailed overview of Roniciclib BAY-1000394 including its chemical properties, health benefits, potential effects, product mechanism, safety, side effects, and dosing information.
Chemical name: (R)-1-(2,6-difluorobenzyl)-3-((S)-((1-isopropylpiperidin-3-yl)amino)methyl)pyrazole-4-carboxamide Molecular formula: C22H29F2N5O Formula weight: 427.50 g/mol CAS No: 1223498-69-8
Top Ten Keywords:
Roniciclib BAY-1000394 is a potent inhibitor of CDK 4/6, enzymes that are crucial for cancer cell proliferation. In preclinical studies, Roniciclib has exhibited strong anti-tumor activity in various forms of cancer such as breast, lung, and pancreatic cancer. It has also demonstrated a low toxicity profile and has not shown any significant side effects in preclinical models. These findings suggest that Roniciclib has the potential to become an effective and safe cancer treatment option.
Roniciclib BAY-1000394 has the potential to inhibit the growth of cancerous tumors by blocking the actions of CDK 4/6. CDK 4/6 inhibitors like Roniciclib are considered to be a new and promising class of drugs for cancer treatment because they selectively target cancer cells without affecting normal cells. It is also believed that combination therapy with CDK 4/6 inhibitors and other cancer treatments such as chemotherapy and immunotherapy may enhance the overall effectiveness of cancer treatment.
Roniciclib BAY-1000394 works by selectively inhibiting CDK 4/6, enzymes that regulate the cell cycle and cell proliferation. By blocking the action of these enzymes, Roniciclib prevents the replication of cancer cells, which ultimately leads to the death of cancerous cells. This mechanism of action has been demonstrated in preclinical studies, where Roniciclib has exhibited significant anti-tumor activity.
In preclinical studies, Roniciclib BAY-1000394 has demonstrated a low toxicity profile and has not shown any significant side effects. However, it is important to note that this drug is still in the early stages of development and has not yet been tested in humans. Therefore, more studies are needed to evaluate its safety in humans.
As mentioned earlier, Roniciclib BAY-1000394 has not shown any significant side effects in preclinical studies. However, it is always possible that new side effects may emerge during clinical trials or after the drug is approved for use. Therefore, it is important for patients to report any unusual symptoms to their healthcare provider.
The optimal dosing regimen for Roniciclib BAY-1000394 has not yet been established. However, preclinical studies have suggested that the drug may be effective at doses ranging from 10 to 30 mg/kg. Further studies are needed to determine the optimal dosing for humans.
Roniciclib BAY-1000394 is a promising drug compound that may offer a new treatment option for various forms of cancer. Its potential to inhibit CDK 4/6, selectively target cancer cells, and enhance the effectiveness of combination therapy make it an attractive candidate for cancer treatment. However, more studies are needed to evaluate its safety and efficacy in humans. If successful, Roniciclib could become an important addition to the arsenal of cancer treatments available to patients.